Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ACD Announces Clinical Study Results Using its RNAscopeâ„¢ Technology

February 28, 2011 By Bio-Medicine.Org

SAN ANTONIO, Feb. 28, 2011 /PRNewswire/ — Advanced Cell
Diagnostics, Inc. (ACD) today announced the results of its clinical
study utilizing RNAscope™ technology to detect human
papillomavirus (HPV) E6/E7 mRNA in routine clinical specimens of
head and neck cancer. HPV status determined by the RNAscope™
HPV test was highly predictive of patient outcome and highly
concordant with that determined by existing methods. Significantly,
the RNAscope™ test under development demonstrated 16% higher
detection sensitivity than the HPV DNA test used in the study.

These results will be presented today at the 100th annual
meeting of United States & Canadian Academy of Pathology (USCAP
2011). The RNAscope™ HPV test detects E6/E7 mRNA from seven
high risk HPV genotypes known to be associated with certain head
and neck cancers. The study included 211 head and neck cancers from
the oropharynx (base of tongue and throat). It compared the
RNAscope™ test with two other tests detecting HPV DNA and the
cellular protein p16. RNAscope™ identified 78% of the cases
to be positive for HPV, compared to 62% and 79% by the HPV DNA and
p16 assays, respectively. HPV-positive tumors as determined by
RNAscope™ were associated with 77% lower risk of death
following standard therapies (hazard ratio = 0.23, p < 0.001 for
overall survival and disease-specific survival), compared to
HPV-negative tumors.

“To determine whether a tumor is caused by HPV, it requires more
than just detecting the presence or absence of the virus. Detecting
transcriptionally active HPV in the tumor cells is critical to
establish its presence as clinically significant,” said Dr. James
Lewis Jr. of Washington University in St. Louis, the principal
investigator in this collaborative study. “The RNAscope™
assay uniquely addresses this clinical need by detecting the viral
E6/E7 mRNAs and allowing their direct visualization in the tumor
cells,” continued Dr. Lewis

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech